Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025
Palvella Therapeutics (NASDAQ:PVLA), a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, will host its Q2 2025 financial results conference call on August 14, 2025, at 8:30 a.m. ET.
The company, which focuses on developing treatments for conditions with no current FDA-approved therapies, will provide both financial results and a corporate update during the call. Investors can access the live webcast with slides through Palvella's website under the "Events & Presentations" section, with a replay available for 90 days after the call.
Palvella Therapeutics (NASDAQ:PVLA), una società biofarmaceutica in fase clinica che sviluppa terapie per malattie genetiche rare della pelle, terrà la sua conferenza telefonica sui risultati finanziari del secondo trimestre 2025 il 14 agosto 2025 alle 8:30 ET.
La società, che si concentra sullo sviluppo di trattamenti per condizioni senza terapie approvate dalla FDA, fornirà durante la chiamata sia i risultati finanziari sia un aggiornamento aziendale. Gli investitori potranno seguire la diretta webcast con le slide sul sito web di Palvella nella sezione "Eventi e Presentazioni", con una replica disponibile per 90 giorni dopo la chiamata.
Palvella Therapeutics (NASDAQ:PVLA), una empresa biofarmacéutica en etapa clínica que desarrolla terapias para enfermedades genéticas raras de la piel, realizará su conferencia telefónica de resultados financieros del segundo trimestre de 2025 el 14 de agosto de 2025 a las 8:30 a.m. ET.
La compañía, que se enfoca en desarrollar tratamientos para condiciones sin terapias aprobadas por la FDA, ofrecerá durante la llamada tanto los resultados financieros como una actualización corporativa. Los inversores podrán acceder a la transmisión en vivo con diapositivas a través del sitio web de Palvella en la sección "Eventos y Presentaciones", con una repetición disponible durante 90 días después de la llamada.
Palvella Therapeutics (NASDAQ:PVLA)는 희귀 유전성 피부 질환 치료제를 개발하는 임상 단계의 바이오제약 회사로, 2025년 8월 14일 오전 8시 30분(동부시간)에 2025년 2분기 재무 실적 컨퍼런스 콜을 개최할 예정입니다.
FDA 승인이 없는 질환 치료제 개발에 집중하는 이 회사는 콜에서 재무 실적과 회사 현황 업데이트를 제공할 것입니다. 투자자들은 Palvella 웹사이트의 "이벤트 및 프레젠테이션" 섹션을 통해 슬라이드와 함께 라이브 웹캐스트에 접속할 수 있으며, 콜 종료 후 90일 동안 다시보기 서비스를 이용할 수 있습니다.
Palvella Therapeutics (NASDAQ:PVLA), une société biopharmaceutique en phase clinique développant des thérapies pour des maladies génétiques rares de la peau, organisera sa conférence téléphonique sur les résultats financiers du deuxième trimestre 2025 le 14 août 2025 à 8h30 ET.
L'entreprise, qui se concentre sur le développement de traitements pour des affections sans thérapies approuvées par la FDA, présentera lors de l'appel à la fois les résultats financiers et une mise à jour d'entreprise. Les investisseurs pourront accéder à la diffusion en direct avec les diapositives via le site web de Palvella dans la section « Événements & Présentations », avec un replay disponible pendant 90 jours après l'appel.
Palvella Therapeutics (NASDAQ:PVLA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Therapien für seltene genetische Hautkrankheiten entwickelt, wird seine Finanzergebnisse für das zweite Quartal 2025 am 14. August 2025 um 8:30 Uhr ET in einer Telefonkonferenz vorstellen.
Das Unternehmen, das sich auf die Entwicklung von Behandlungen für Erkrankungen ohne derzeit von der FDA zugelassene Therapien spezialisiert hat, wird während des Anrufs sowohl finanzielle Ergebnisse als auch ein Unternehmensupdate präsentieren. Investoren können den Live-Webcast mit Folien über die Website von Palvella im Bereich "Events & Presentations" verfolgen; eine Aufzeichnung ist 90 Tage nach dem Anruf verfügbar.
- None.
- None.
WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025.
Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, August 14, 2025, to discuss financial results and provide a corporate update.
To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" section of Palvella’s website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company’s website at www.palvellatx.com.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN
QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
FAQ
When is Palvella Therapeutics (PVLA) Q2 2025 earnings call?
How can I access Palvella Therapeutics (PVLA) Q2 2025 earnings call?
What does Palvella Therapeutics (PVLA) specialize in?
How long will Palvella Therapeutics (PVLA) Q2 2025 earnings call replay be available?
